BACKGROUND: Cervical cancer is the second largest cause of cancer deaths in women worldwide. It is now evident that persistent infection with high-risk human papillomavirus (HPV) is necessary for the development and maintenance of cervical cancer. Thus, effective vaccination against HPV represents an opportunity to restrain cervical cancer and other important cancers. The FDA recently approved the HPV vaccine Gardasil for the preventive control of HPV, using HPV virus-like particles (VLP) to generate neutralizing antibodies against major capsid protein, L1. However, prophylactic HPV vaccines do not have therapeutic effects against pre-existing HPV infections and HPV-associated lesions. Furthermore, due to the considerable burden of HPV infections worldwide, it would take decades for preventive vaccines to affect the prevalence of cervical cancer. Thus, in order to speed up the control of cervical cancer and treat current infections, the continued development of therapeutic vaccines against HPV is critical. Therapeutic HPV vaccines can potentially eliminate pre-existing lesions and malignant tumors by generating cellular immunity against HPV-infected cells that express early viral proteins such as E6 and E7. OBJECTIVE: This review discusses the future directions of therapeutic HPV vaccine approaches for the treatment of established HPV-associated malignancies, with emphasis on current progress of HPV vaccine clinical trials. METHODS: Relevant literature is discussed. RESULTS/ CONCLUSION: Though their development has been challenging, many therapeutic HPV vaccines have been shown to induce HPV-specific antitumor immune responses in preclinical animal models and several promising strategies have been applied in clinical trials. With continued progress in the field of vaccine development, HPV therapeutic vaccines may provide a potentially promising approach for the control of lethal HPV-associated malignancies.
BACKGROUND:Cervical cancer is the second largest cause of cancer deaths in women worldwide. It is now evident that persistent infection with high-risk human papillomavirus (HPV) is necessary for the development and maintenance of cervical cancer. Thus, effective vaccination against HPV represents an opportunity to restrain cervical cancer and other important cancers. The FDA recently approved the HPV vaccine Gardasil for the preventive control of HPV, using HPV virus-like particles (VLP) to generate neutralizing antibodies against major capsid protein, L1. However, prophylactic HPV vaccines do not have therapeutic effects against pre-existing HPV infections and HPV-associated lesions. Furthermore, due to the considerable burden of HPV infections worldwide, it would take decades for preventive vaccines to affect the prevalence of cervical cancer. Thus, in order to speed up the control of cervical cancer and treat current infections, the continued development of therapeutic vaccines against HPV is critical. Therapeutic HPV vaccines can potentially eliminate pre-existing lesions and malignant tumors by generating cellular immunity against HPV-infected cells that express early viral proteins such as E6 and E7. OBJECTIVE: This review discusses the future directions of therapeutic HPV vaccine approaches for the treatment of established HPV-associated malignancies, with emphasis on current progress of HPV vaccine clinical trials. METHODS: Relevant literature is discussed. RESULTS/ CONCLUSION: Though their development has been challenging, many therapeutic HPV vaccines have been shown to induce HPV-specific antitumor immune responses in preclinical animal models and several promising strategies have been applied in clinical trials. With continued progress in the field of vaccine development, HPV therapeutic vaccines may provide a potentially promising approach for the control of lethal HPV-associated malignancies.
Authors: Romana Mikysková; Marie Indrová; Jana Símová; Tána Jandlová; Jana Bieblová; Pavel Jinoch; Jan Bubeník; Vladimír Vonka Journal: Int J Oncol Date: 2004-01 Impact factor: 5.650
Authors: Tae Woo Kim; Chien-Fu Hung; David A K Boyd; Liangmei He; Cheng-Tao Lin; Dion Kaiserman; Phillip I Bird; T-C Wu Journal: Cancer Res Date: 2004-01-01 Impact factor: 12.701
Authors: Janet L Brandsma; Mark Shlyankevich; Lixin Zhang; Martin D Slade; Edward C Goodwin; Woei Peh; Albert B Deisseroth Journal: J Virol Date: 2004-01 Impact factor: 5.103
Authors: Natalia Rubinstein; Mariano Alvarez; Norberto W Zwirner; Marta A Toscano; Juan M Ilarregui; Alicia Bravo; José Mordoh; Leonardo Fainboim; Osvaldo L Podhajcer; Gabriel A Rabinovich Journal: Cancer Cell Date: 2004-03 Impact factor: 31.743
Authors: Francisco Garcia; Karl Ulrich Petry; Laila Muderspach; Michael A Gold; Patricia Braly; Christopher P Crum; Marianne Magill; Michael Silverman; Robert G Urban; Mary Lynne Hedley; Kathleen J Beach Journal: Obstet Gynecol Date: 2004-02 Impact factor: 7.661
Authors: Laura Martin-Gomez; Anna R Giuliano; William J Fulp; Jimmy Caudell; Michelle Echevarria; Bradley Sirak; Martha Abrahamsen; Kimberly A Isaacs-Soriano; Juan C Hernandez-Prera; Bruce M Wenig; Kathryn Vorwald; Caitlin P McMullen; J Trad Wadsworth; Robbert J Slebos; Christine H Chung Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-05-01 Impact factor: 6.223
Authors: Kent A Smith; Brenna L Meisenburg; Victor L Tam; Robb R Pagarigan; Raymond Wong; Diljeet K Joea; Liz Lantzy; Mayra A Carrillo; Todd M Gross; Uriel M Malyankar; Chih-Sheng Chiang; Diane M Da Silva; Thomas M Kündig; W Martin Kast; Zhiyong Qiu; Adrian Bot Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531
Authors: Antonia Radaelli; Eleana Pozzi; Sole Pacchioni; Carlo Zanotto; Carlo De Giuli Morghen Journal: J Transl Med Date: 2010-04-21 Impact factor: 5.531